Abstract:Network-based computational method, with the emphasis on biomolecular interactions and biological data integration, has succeeded in drug development and created new directions, such as drug repositioning and drug combination.Drug repositioning, that is finding new uses for existing drugs to treat more patients, offers time, cost and efficiency benefits in drug development, especially when in silico techniques are used.MicroRNAs (miRNAs) play important roles in multiple biological processes and have attracted much scientific attention recently.Moreover, cumulative studies demonstrate that the mature miRNAs as well as their precursors can be targeted by small molecular drugs.At the same time, human diseases result from the disordered interplay of tissue-and cell lineage-specific processes.However, few computational researches predict drug-disease potential relationships based on miRNA data and tissue specificity.Therefore, based on miRNA data and the tissue specificity of diseases, we propose a new method named as miTS to predict the potential treatments for diseases.Firstly, based on miRNAs data, target genes and information of FDA (Food and Drug Administration) approved drugs, we evaluate the relationships between miRNAs and drugs in the tissue-specific PPI (protein-protein) network.Then, we construct a tripartite network: drug-miRNA-disease Finally, we obtain the potential drug-disease associations based on the tripartite network.In this paper, we take breast cancer as case study and focus on the top-30 predicted drugs.25 of them (83.3%) are found having known connections with breast cancer in CTD (Comparative Toxicogenomics Database) benchmark and the other 5 drugs are potential drugs for breast cancer.We further evaluate the 5 newly predicted drugs from clinical records, literature mining, KEGG pathways enrichment analysis and overlapping genes between enriched pathways.For each of the 5 new drugs, strongly supported evidences can be found in three or more aspects.In particular, Regorafenib (DB08896) has 15 overlapping KEGG pathways with breast cancer and their p-values are all very small.In addition, whether in the literature curation or clinical validation, Regorafenib has a strong correlation with breast cancer.All the facts show that Regorafenib is likely to be a truly effective drug, worthy of our further study.It further follows that our method miTS is effective and practical for predicting new drug indications, which will provide potential values for treatments of complex diseases.

Integration of a prognostic gene module with a drug sensitivity module to identify drugs that could be repurposed for breast cancer therapy.

Identifying Breast Cancer-induced Gene Perturbations and its Application in Guiding Drug Repurposing

Repositioning Drugs For Breast Cancer Based On The Identification Of Cancer Related Signaling Pathways

Drug Repurposing for Cancer Treatment Through Global Propagation with a Greedy Algorithm in a Multilayer Network

Drug repurposing against breast cancer by integrating drug-exposure expression profiles and drug–drug links based on graph neural network

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

Estrogen receptor—positive breast cancer survival prediction and analysis of resistance–related genes introduction

A drug repurposing method based on inhibition effect on gene regulatory network

Pre-Clinical Drug Prioritization Via Prognosis-Guided Genetic Interaction Networks

Peer Review #2 of "estrogen Receptor—positive Breast Cancer Survival Prediction and Analysis of Resistance–related Genes Introduction (V0.1)"

Predicting potential treatments for complex diseases based on miRNA and tissue specificity

Integrated Metabolic Profiling and Gene Expression Analysis Reveals Therapeutic Modalities in Breast Cancer

Identifying Prognostic Features by Bottom-Up Approach and Correlating to Drug Repositioning.

Informatics on Drug Repurposing for Breast Cancer.

A network medicine approach for identifying diagnostic and prognostic biomarkers and exploring drug repurposing in human cancer

Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach

Predicting Potential Drugs for Breast Cancer Based on Mirna and Tissue Specificity

Ranking Breast Cancer Drugs and Biomarkers Identification Using Machine Learning and Pharmacogenomics

Computationally repurposing drugs for breast cancer subtypes using a network-based approach

Prioritization of Candidate Cancer Drugs Based on a Drug Functional Similarity Network Constructed by Integrating Pathway Activities and Drug Activities